Subscribe To

Price Alert Latest News Economic Calendar News

IMAB / I-Mab: Why This Company Trades At A Third The Value Of Its Cash

Chinese biotech company I-Mab faces challenges in attracting US capital due to lack of transparency and difficulty in valuing its pipeline. I-Mab has a late-stage pipeline with 20 assets and over $400 million in cash, but its market cap is only around $126 million. The company's advanced products, such as Felzartamab and Eftansomatropin Alfa, have limited trial data available, making it difficult for American investors to assess the company properly. Read More

Demo Live Account See Partner Details

Content Topics

Mab

This

Company

Trades

Third

Value

Cash

I mab

Stock

IMAB

Posted: Sep 13 2023, 16:59

Author Name: Seeking Alpha

IMAB News

By Seeking Alpha
September 13, 2023

I-Mab: Why This Company Trades At A Third The Value Of Its Cash

Chinese biotech company I-Mab faces challenges in attracting US capital due to lack of transparency and difficulty in valuing its pipeline. I-Mab has

By Market Watch
June 27, 2023

Theft in open court: How a fight over lifesaving drugs led to charges of brazen industrial espionage

A Chinese developer of cutting-edge cancer drugs has accused a chief competitor of stealing its trade secrets by posing as an expert witness in an arb

By Seeking Alpha
August 30, 2022

I-Mab (IMAB) H1 2022 Earnings Call Transcript

I-Mab (NASDAQ:IMAB ) H1 2022 Earnings Conference Call August 30, 2022 9:15 AM ET Company Participants Tyler Ehler – Senior Director of Investor Rela

By Seeking Alpha
June 23, 2022

I-Mab Valuation Offers A Biotech Investment Opportunity

The biotech indices have fallen considerably. Many biotechs are trading with negative enterprise values despite unprecedented innovation in the biotec

By Seeking Alpha
March 29, 2022

I-Mab (IMAB) CEO Management on Q4 2021 Results - Earnings Call Transcript

By PRNewsWire
March 18, 2022

I-Mab to Report Full Year 2021 Financial Results and Provide Corporate Update on March 29, 2022

SHANGHAI and GAITHERSBURG, MD, March 18, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committ

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.